Table 2

Demographic and other baseline characteristics: intention-to-treat population

CharacteristicPlacebo (n=63)Vedolizumab (n=64)Total (N=127)
Sex, n (%)
 Male43 (68)44 (69)87 (69)
 Female20 (32)20 (31)40 (31)
Race, n (%)
 White56 (89)62 (97)118 (93)
 Black1 (2)1 (2)2 (2)
 Asian2 (3)1 (2)3 (2)
 Other4 (6)04 (3)
Age, years
 Mean (SD)27.3 (5.33)27.7 (5.64)27.5 (5.47)
 Median (range)26.0 (19–38)28.5 (19–39)27.0 (19–39)
Weight, kg
 Mean (SD)76.2 (11.53)75.0 (13.48)75.6 (12.51)
 Median (range)75.4 (54.5–112.5)73.9 (47.9–107.2)74.5 (47.9–112.5)
BMI, kg/m2
 Mean (SD)25.4 (2.71)24.8 (3.34)25.1 (3.04)
 Median (range)25.0 (20.0–31.8)24.6 (18.5–31.9)24.8 (18.5–31.9)
  • The intention-to-treat population was defined as all participants who received any amount of study drug (vedolizumab or placebo) based on their randomised study drug assignment.

  • BMI, body mass index.